Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease

Rebecca A. Wilshusen, R Lee Mosley

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Innate and adaptive immunity affect the pathogenesis of Parkinson's disease (PD). In particular, the activation of microglia that feed neuroinflammation and oxidative stress influences the degeneration of dopaminergic neurons along the nigrostriatal axis during disease. Activated microglia that proximate degenerating neurons within the substantia nigra are a hallmark of PD. Other PD hallmarks include neuronal Lewy body inclusions composed primarily of aggregated ubiquitin and neuronal proteins. Under inflammatory conditions, oxidative or nitrative modifications of neuronal proteins, such as ?-synuclein, lead to misfolding and formation of neurotoxic species that accumulate within the neuron. Release of misfolded proteins from injured or dead neurons intensifies neuroinflammation and neuronal injury within the surrounding area. Moreover, once in the peripheral immune compartments, processing and presentation of modified proteins, such as nitrated ?-synuclein by dendritic cells, induce effector T cells to those nitrated epitopes that act as neoantigens. Robust effector T cell immune responses against nitrated or modified self-proteins and migration of those effector T cells to inflammatory sites exacerbate neuroinflammation and dopaminergic neurodegeneration, which lead to accelerated disease progression. The links between T cell immunity and nigrostriatal neurodegeneration are supported by laboratory and animal models as well as human investigations of immune-associated biomarkers in the spinal fluid, peripheral blood, and brain tissue of patients with idiopathic or familial forms of PD. Regulatory T cells modulate both innate and effector T cell-mediated immunity to attenuate neuroinflammation and alleviate neurodegeneration along the nigrostriatal axis. Thus, harnessing proinflammatory and neurotoxic effector immune responses with drugs, vaccination, or immunomodulation affords promising therapeutic strategies either alone as an interdictory therapy or in combination as adjunctive therapy in the context of neuronal replacement. Herein immune-mediated inflammation, oxidative stress, and neurodegeneration as linked to PD pathogenesis are examined as well as the potential benefits of efficacious immune regulatory control over those neurotoxic processes.

Original languageEnglish (US)
Title of host publicationNeuroinflammation and Neurodegeneration
PublisherSpringer New York
Pages119-142
Number of pages24
Volume9781493910717
ISBN (Print)9781493910717, 1493910701, 9781493910700
DOIs
StatePublished - Apr 1 2014

Fingerprint

Parkinson Disease
T-Lymphocytes
Synucleins
Microglia
Proteins
Neurons
Oxidative Stress
Lewy Bodies
Immunomodulation
Dopaminergic Neurons
Adaptive Immunity
Substantia Nigra
Regulatory T-Lymphocytes
Ubiquitin
Innate Immunity
Cellular Immunity
Dendritic Cells
Disease Progression
Epitopes
Immunity

Keywords

  • Adaptive immunity
  • Dopaminergic
  • Effector T cells
  • Innate immunity
  • Microglia
  • Neurodegeneration
  • Neuroinflammation
  • Parkinson's disease
  • Regulatory T cells
  • Teffs
  • Tregs

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Wilshusen, R. A., & Mosley, R. L. (2014). Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease. In Neuroinflammation and Neurodegeneration (Vol. 9781493910717, pp. 119-142). Springer New York. https://doi.org/10.1007/978-1-4939-1071-7_7

Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease. / Wilshusen, Rebecca A.; Mosley, R Lee.

Neuroinflammation and Neurodegeneration. Vol. 9781493910717 Springer New York, 2014. p. 119-142.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wilshusen, RA & Mosley, RL 2014, Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease. in Neuroinflammation and Neurodegeneration. vol. 9781493910717, Springer New York, pp. 119-142. https://doi.org/10.1007/978-1-4939-1071-7_7
Wilshusen RA, Mosley RL. Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease. In Neuroinflammation and Neurodegeneration. Vol. 9781493910717. Springer New York. 2014. p. 119-142 https://doi.org/10.1007/978-1-4939-1071-7_7
Wilshusen, Rebecca A. ; Mosley, R Lee. / Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease. Neuroinflammation and Neurodegeneration. Vol. 9781493910717 Springer New York, 2014. pp. 119-142
@inbook{be8dbc903c724618a27f04856983f68b,
title = "Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease",
abstract = "Innate and adaptive immunity affect the pathogenesis of Parkinson's disease (PD). In particular, the activation of microglia that feed neuroinflammation and oxidative stress influences the degeneration of dopaminergic neurons along the nigrostriatal axis during disease. Activated microglia that proximate degenerating neurons within the substantia nigra are a hallmark of PD. Other PD hallmarks include neuronal Lewy body inclusions composed primarily of aggregated ubiquitin and neuronal proteins. Under inflammatory conditions, oxidative or nitrative modifications of neuronal proteins, such as ?-synuclein, lead to misfolding and formation of neurotoxic species that accumulate within the neuron. Release of misfolded proteins from injured or dead neurons intensifies neuroinflammation and neuronal injury within the surrounding area. Moreover, once in the peripheral immune compartments, processing and presentation of modified proteins, such as nitrated ?-synuclein by dendritic cells, induce effector T cells to those nitrated epitopes that act as neoantigens. Robust effector T cell immune responses against nitrated or modified self-proteins and migration of those effector T cells to inflammatory sites exacerbate neuroinflammation and dopaminergic neurodegeneration, which lead to accelerated disease progression. The links between T cell immunity and nigrostriatal neurodegeneration are supported by laboratory and animal models as well as human investigations of immune-associated biomarkers in the spinal fluid, peripheral blood, and brain tissue of patients with idiopathic or familial forms of PD. Regulatory T cells modulate both innate and effector T cell-mediated immunity to attenuate neuroinflammation and alleviate neurodegeneration along the nigrostriatal axis. Thus, harnessing proinflammatory and neurotoxic effector immune responses with drugs, vaccination, or immunomodulation affords promising therapeutic strategies either alone as an interdictory therapy or in combination as adjunctive therapy in the context of neuronal replacement. Herein immune-mediated inflammation, oxidative stress, and neurodegeneration as linked to PD pathogenesis are examined as well as the potential benefits of efficacious immune regulatory control over those neurotoxic processes.",
keywords = "Adaptive immunity, Dopaminergic, Effector T cells, Innate immunity, Microglia, Neurodegeneration, Neuroinflammation, Parkinson's disease, Regulatory T cells, Teffs, Tregs",
author = "Wilshusen, {Rebecca A.} and Mosley, {R Lee}",
year = "2014",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-1071-7_7",
language = "English (US)",
isbn = "9781493910717",
volume = "9781493910717",
pages = "119--142",
booktitle = "Neuroinflammation and Neurodegeneration",
publisher = "Springer New York",

}

TY - CHAP

T1 - Innate and adaptive immune-mediated neuroinflammation and neurodegeneration in parkinson's disease

AU - Wilshusen, Rebecca A.

AU - Mosley, R Lee

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Innate and adaptive immunity affect the pathogenesis of Parkinson's disease (PD). In particular, the activation of microglia that feed neuroinflammation and oxidative stress influences the degeneration of dopaminergic neurons along the nigrostriatal axis during disease. Activated microglia that proximate degenerating neurons within the substantia nigra are a hallmark of PD. Other PD hallmarks include neuronal Lewy body inclusions composed primarily of aggregated ubiquitin and neuronal proteins. Under inflammatory conditions, oxidative or nitrative modifications of neuronal proteins, such as ?-synuclein, lead to misfolding and formation of neurotoxic species that accumulate within the neuron. Release of misfolded proteins from injured or dead neurons intensifies neuroinflammation and neuronal injury within the surrounding area. Moreover, once in the peripheral immune compartments, processing and presentation of modified proteins, such as nitrated ?-synuclein by dendritic cells, induce effector T cells to those nitrated epitopes that act as neoantigens. Robust effector T cell immune responses against nitrated or modified self-proteins and migration of those effector T cells to inflammatory sites exacerbate neuroinflammation and dopaminergic neurodegeneration, which lead to accelerated disease progression. The links between T cell immunity and nigrostriatal neurodegeneration are supported by laboratory and animal models as well as human investigations of immune-associated biomarkers in the spinal fluid, peripheral blood, and brain tissue of patients with idiopathic or familial forms of PD. Regulatory T cells modulate both innate and effector T cell-mediated immunity to attenuate neuroinflammation and alleviate neurodegeneration along the nigrostriatal axis. Thus, harnessing proinflammatory and neurotoxic effector immune responses with drugs, vaccination, or immunomodulation affords promising therapeutic strategies either alone as an interdictory therapy or in combination as adjunctive therapy in the context of neuronal replacement. Herein immune-mediated inflammation, oxidative stress, and neurodegeneration as linked to PD pathogenesis are examined as well as the potential benefits of efficacious immune regulatory control over those neurotoxic processes.

AB - Innate and adaptive immunity affect the pathogenesis of Parkinson's disease (PD). In particular, the activation of microglia that feed neuroinflammation and oxidative stress influences the degeneration of dopaminergic neurons along the nigrostriatal axis during disease. Activated microglia that proximate degenerating neurons within the substantia nigra are a hallmark of PD. Other PD hallmarks include neuronal Lewy body inclusions composed primarily of aggregated ubiquitin and neuronal proteins. Under inflammatory conditions, oxidative or nitrative modifications of neuronal proteins, such as ?-synuclein, lead to misfolding and formation of neurotoxic species that accumulate within the neuron. Release of misfolded proteins from injured or dead neurons intensifies neuroinflammation and neuronal injury within the surrounding area. Moreover, once in the peripheral immune compartments, processing and presentation of modified proteins, such as nitrated ?-synuclein by dendritic cells, induce effector T cells to those nitrated epitopes that act as neoantigens. Robust effector T cell immune responses against nitrated or modified self-proteins and migration of those effector T cells to inflammatory sites exacerbate neuroinflammation and dopaminergic neurodegeneration, which lead to accelerated disease progression. The links between T cell immunity and nigrostriatal neurodegeneration are supported by laboratory and animal models as well as human investigations of immune-associated biomarkers in the spinal fluid, peripheral blood, and brain tissue of patients with idiopathic or familial forms of PD. Regulatory T cells modulate both innate and effector T cell-mediated immunity to attenuate neuroinflammation and alleviate neurodegeneration along the nigrostriatal axis. Thus, harnessing proinflammatory and neurotoxic effector immune responses with drugs, vaccination, or immunomodulation affords promising therapeutic strategies either alone as an interdictory therapy or in combination as adjunctive therapy in the context of neuronal replacement. Herein immune-mediated inflammation, oxidative stress, and neurodegeneration as linked to PD pathogenesis are examined as well as the potential benefits of efficacious immune regulatory control over those neurotoxic processes.

KW - Adaptive immunity

KW - Dopaminergic

KW - Effector T cells

KW - Innate immunity

KW - Microglia

KW - Neurodegeneration

KW - Neuroinflammation

KW - Parkinson's disease

KW - Regulatory T cells

KW - Teffs

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=84929915099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929915099&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1071-7_7

DO - 10.1007/978-1-4939-1071-7_7

M3 - Chapter

SN - 9781493910717

SN - 1493910701

SN - 9781493910700

VL - 9781493910717

SP - 119

EP - 142

BT - Neuroinflammation and Neurodegeneration

PB - Springer New York

ER -